MorphoSys AG (MOR) 뉴스

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

MorphoSys AG Reports First Quarter 2024 Financial Results

– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of €...

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94...

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value – Sold all...

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus...

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction...

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

– Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023 – Monjuvi® U.S. net...

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

– Monjuvi® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of...

MorphoSys AG Reports First Quarter 2023 Financial Results

– Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of...